Not just a label -biology driven approach that fits You!

The PIRA panel pushed past the old categories and into how MS actually behaves. Even when the disease "looks stable," patients often feel worse and PIRA is finally giving that lived experience a name and a measurement. Biomarkers like NfL are starting to show us the part of the MS iceberg that sits below the waterline, and BTK inhibitors are emerging as a hopeful next chapter. The takeaway: "stable" deserves a rethink, smouldering inflammation is real, and personalised care isn't a buzzword, it's the destination.